GlassScriptPhysician profile
Allison A Linton
NPI 1528206018
$2,567.52
in general payments reported to CMS, 2019-2025
49 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $336 · 2023: $642 · 2024: $949 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.94 | 2022-2024 | |
| Lilly USA, LLC | $226.41 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $161.25 | 2024-2025 | Voquezna |
| Grifols USA, LLC | $109.81 | 2021-2023 | Prolastin-C Liquid |
| Lundbeck LLC | $105.30 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $102.58 | 2023-2024 | Ultomiris |
| Novo Nordisk INC | $92.08 | 2024-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $91.09 | 2021-2023 | Amplatzer Amulet |
| Radius Health, INC. | $88.25 | 2023-2024 | Tymlos |
| Ucb, INC. | $75.30 | 2022-2025 | Rystiggo, Cimzia |
| Astrazeneca Pharmaceuticals LP | $74.93 | 2024-2025 | Airsupra |
| Argenx US, INC. | $67.46 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.38 | 2021-2022 | |
| Banner Life Sciences, LLC | $64.38 | 2023-2024 | |
| Tolmar, INC. | $61.97 | 2025 | Jatenzo |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.91 | 2021-2024 | Injectafer |
| Pfizer INC. | $52.17 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.21 | 2023-2024 | Ofev, Cyltezo |
| Sanofi-Aventis U.S. LLC | $43.19 | 2023-2025 | |
| Amgen INC. | $42.34 | 2023-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $40.05 | 2021-2022 | |
| Astellas Pharma US INC | $38.00 | 2025 | Veozah |
| Mallinckrodt Hospital Products INC. | $34.41 | 2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $32.71 | 2023-2024 | Opsumit, Uptravi |
| Tg Therapeutics, INC. | $32.02 | 2024 | |
| Organon LLC | $31.47 | 2023-2024 | Renflexis |
| Csl Behring | $30.69 | 2022-2025 | Hizentra |
| Medtronic, INC. | $29.53 | 2022-2025 | Inceptiv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.71 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $27.54 | 2022 | |
| Glaxosmithkline, LLC. | $25.47 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $24.27 | 2021 | |
| Corium, LLC | $23.97 | 2022 | |
| Madrigal Pharmaceuticals | $22.90 | 2025 | Rezdiffra |
| Emd Serono, INC. | $21.49 | 2023 | Mavenclad |
| Neurocrine Biosciences, INC. | $20.12 | 2023 | Ingrezza, Ongentys |
| Genzyme Corporation | $19.52 | 2022 | |
| Janssen Biotech, INC. | $17.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.87 | 2023 | Dupixent |
| Insightec,INC | $16.19 | 2025 | Exablate |
| Dexcom, INC. | $15.43 | 2025 | Dexcom G6 Transmitter |
| Insmed, INC. | $15.14 | 2021 | |
| Baxter Healthcare | $14.88 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $14.06 | 2021 | |
| Pharmacosmos Therapeutics INC. | $13.96 | 2023 | Monoferric |
| Axsome Therapeutics, INC. | $13.80 | 2023 | Auvelity |
| Sk Life Science, INC. | $13.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.02 | 2022 | |
| The Binding Site INC. | $11.11 | 2025 | Freelite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Linton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.